Latest Us Market Entry News

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Smart Parking Limited has reported robust H1 FY25 results, underpinned by a strategic acquisition of Peak Parking LP and a fully underwritten $45 million equity raise to fund its US expansion.

Smart Parking Limited is set to expand its global footprint by acquiring US-based Peak Parking LP for up to USD 36 million, backed by a fully underwritten equity raise and expanded debt facility. The deal promises significant EPS accretion and strategic growth opportunities in the lucrative US parking market.

Ovanti Limited has secured board approval for its ambitious US market entry plan targeting $500 million in total transaction volumes within two years, focusing on underserved consumers in the Southern States.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

Ovanti Limited has made significant strides in its plan to enter the US Buy Now Pay Later market, delivering a comprehensive strategic report and strengthening its executive team to support expansion.

Echo IQ confirms the material significance of its pre-submission FDA meeting for EchoSolv HF, marking a pivotal step toward US market entry and commercialisation.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.

Echo IQ Limited has secured FDA clearance for its EchoSolv AS technology and appointed a US-based CEO, marking a pivotal shift towards commercialisation in the American healthcare market.

Identitii reports solid quarterly progress highlighted by a strategic new director appointment, US market expansion, and a successful $1.8 million capital raise, underpinning its path toward profitability.